International Journal of Hematology

, Volume 84, Issue 3, pp 276–281 | Cite as

Autologous Peripheral Blood Stem Cell Transplantation for Severe Multiple Sclerosis

Article

Abstract

We describe the results of a clinical trial to evaluate the feasibility and toxicity of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with progressive multiple sclerosis (MS). Fifteen patients (all patients with secondary progressive MS) were enrolled. The median expanded disability status scale (EDSS) score at baseline was 6.0 (range, 4.5–7.5). Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. In 9 patients, CD34+ cell selection was performed with a CliniMACS cell selection system, and 6 patients accepted infusion of unmodified peripheral blood stem cells. The modified BEAM (carmustine, teniposide, cytarabine, and melphalan) was the sole conditioning regimen used. The adverse effects included infections, mucositis, transient hepatotoxicity, and diarrhea. Three patients had flares of neurologic deterioration during mobilization, 8 patients had the same manifestation during transplantation, and 2 patients had similar flares within 3 months of transplantation. Six patients experienced continuous neurologic improvement after transplantation, 5 patients experienced neurologic progression, and 4 patients had stabilization of their disease. The confirmed progression-free rate was 63.8% at 49 months. The results of lymphocyte purging were no better than for no purging. Auto-HSCT proved to be safe and beneficial for some MS patients. Further studies are needed to establish the merit of this procedure for MS patients.

Key words

Multiple sclerosis Autologous hematopoietic stem cell transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lau KK, Wong LK, Li LS, Chan YW, Li HL, Wong V. Epidemio-logical study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J. 2002;8:77–80.PubMedGoogle Scholar
  2. 2.
    Hou JB, Zhang ZX. Prevalence of multiple sclerosis: a door-to-door survey in Lan Cang La Hu Zu Autonomous County, Yunnan Province of China. Neuroepidemiology. 1992;11:52.PubMedGoogle Scholar
  3. 3.
    Hung TP, Landsborough D, Hsi MS. Multiple sclerosis amongst Chinese in Taiwan. J Neurol Sci. 1976;27:459–484.CrossRefGoogle Scholar
  4. 4.
    Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol. 2001;13:597–600.CrossRefGoogle Scholar
  5. 5.
    Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol. 2000;247:691–695.CrossRefGoogle Scholar
  6. 6.
    Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol. 2000;247:376–382.CrossRefGoogle Scholar
  7. 7.
    Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–1568.CrossRefGoogle Scholar
  8. 8.
    Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting close to a cure? Int J Hematol. 2002;76(suppl 1):226–247.CrossRefGoogle Scholar
  9. 9.
    Openshaw H, Nash RA, McSweeney PA. High-dose immunosup-pression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant. 2002;8:233–248.CrossRefGoogle Scholar
  10. 10.
    Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 1996;18:1029–1034.PubMedGoogle Scholar
  11. 11.
    Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873–881.CrossRefGoogle Scholar
  12. 12.
    Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. 2002;8:955–962.CrossRefGoogle Scholar
  13. 13.
    Openshaw H, Hinton DR, Slatkin NE, Bieman PJ, Hoffman FM, Snyder DS. Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation. Bone Marrow Transplant. 1991;7:411–414.PubMedGoogle Scholar
  14. 14.
    Fassas A, Passweg JR, Anagnostopoulos A, et al, for the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol. 2002;249:1088–1097.CrossRefGoogle Scholar
  15. 15.
    Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosup-pressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102:2364–2372.CrossRefGoogle Scholar
  16. 16.
    Openshaw H, Stuve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54:2147–2150.CrossRefGoogle Scholar
  17. 17.
    Burt RK, Fassas A, Snowden JA, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 2001;28:1–12.CrossRefGoogle Scholar
  18. 18.
    Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems, and perspectives. Brain. 1997;120:865–916.CrossRefGoogle Scholar
  19. 19.
    Kusnierz-Glaz CR, Still BJ, Amano M, et al. Granulocyte colony-stimulating factor-induced co-mobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood. 1997;89:2586–2595.PubMedGoogle Scholar
  20. 20.
    Pan L, Delmonte J Jr, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422–4429.PubMedGoogle Scholar
  21. 21.
    Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning: an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma. 1997;25:217–224.CrossRefGoogle Scholar
  22. 22.
    Abu-Ghosh A, Goldman S, Slone V, et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 1999;24:535–544.CrossRefGoogle Scholar
  23. 23.
    Saiz A, Blanco Y, Carreras E, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 2004;62:282–284.CrossRefGoogle Scholar
  24. 24.
    Burks JS, Amason BG, Coyle PK, Ford CC, Noronha A, Rammohan KW. Issues and practices in multiple sclerosis. Neurorehabil Neural Repair. 2002;16:307–320.CrossRefGoogle Scholar
  25. 25.
    Kalman B, Lubin FD. The genetics of multiple sclerosis: a review. Biomed Pharmacother. 1999;53:358–370.CrossRefGoogle Scholar
  26. 26.
    Friedman JE, Lyons MJ, Cu G, et al. The association of the human herpesvirus-6 and MS. Mult Scler. 1999;5:355–362.CrossRefGoogle Scholar
  27. 27.
    Sriram S, Stratton CW, Yao SY, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999;46:6–14.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  1. 1.Department of HematologyXuan Wu Hospital, Capital University of Medical ScienceBeijingP. R. China
  2. 2.Departments of NeurologyXuanWu Hospital, Capital University of Medical SciencesP. R. China
  3. 3.Peking University Institute of Hematology & People’s HospitalBeijingP. R. China

Personalised recommendations